The drug: Alpharadin
The disease: Cancer
The developers: Bayer, Algeta
Peak sales potential: $1 billion-plus

Just days ago, Alpharadin was back in the news with new data analyses indicating that it could have broad use in prostate cancer. Investigators have been studying Alpharadin, or radium-223 dichloride, as a potential treatment for bone metastases that result from prostate cancer.

The treatment has already produced solid survival data as well as evidence of delayed bone metastases. The drug earned some serious kudos at a major European cancer meeting last year.

For Bayer, which struck an $800 million licensing pact on Alpharadin three years ago, its clinical success is supremely important. Bayer, which markets Nexavar in partnership with Onyx ($ONXX), also just scored an approval for regorafenib (now Stivarga). Another approval in cancer would go a long way to demonstrating its success in building a multiproduct cancer franchise. And company execs couldn't be happier about its prospects.

Not all analysts, though, are quite so sure that Alpharadin will join the blockbuster club. But it will likely get its shot.

For more:
Bayer's blockbuster Alpharadin may roil fast-changing prostate cancer field
Bayer, Algeta shares spike as FDA fast-tracks blockbuster hopeful
Bayer snares Algeta's lead cancer med in $800M pact
Bayer, Onyx nab speedy FDA OK for regorafenib, prices at $9,350


Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.